Wedbush Reiterates Neutral Rating for Vera Therapeutics (NASDAQ:VERA)

Vera Therapeutics (NASDAQ:VERA)‘s stock had its “neutral” rating reissued by equities research analysts at Wedbush in a research note issued on Monday,Benzinga reports. They currently have a $34.00 target price on the stock. Wedbush’s target price points to a potential upside of 7.49% from the company’s current price.

Other research analysts have also issued research reports about the stock. Guggenheim lifted their price target on shares of Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. HC Wainwright cut their price target on Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, August 12th. Bank of America upped their price objective on Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. TD Cowen upped their price objective on Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $81.15.

Vera Therapeutics Price Performance

VERA opened at $31.63 on Monday. The company has a fifty day moving average price of $36.38 and a two-hundred day moving average price of $38.45. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92. The firm has a market capitalization of $2.28 billion, a PE ratio of -5.40 and a beta of 0.92. Vera Therapeutics has a 52 week low of $21.15 and a 52 week high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($1.58) by $0.06. During the same period last year, the business posted ($1.20) earnings per share. As a group, analysts anticipate that Vera Therapeutics will post -6.46 earnings per share for the current year.

Insider Activity

In other news, CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the completion of the sale, the chief executive officer directly owned 151,994 shares in the company, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vera Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Los Angeles Capital Management LLC bought a new stake in shares of Vera Therapeutics during the 4th quarter valued at $46,000. Quantbot Technologies LP acquired a new position in shares of Vera Therapeutics in the 2nd quarter valued at approximately $51,000. Aster Capital Management DIFC Ltd bought a new position in shares of Vera Therapeutics in the fourth quarter worth about $71,000. Tower Research Capital LLC TRC lifted its stake in Vera Therapeutics by 192.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after purchasing an additional 2,757 shares during the last quarter. Finally, Sandia Investment Management LP acquired a new stake in Vera Therapeutics in the fourth quarter valued at approximately $127,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.